Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion
Open Access
- 1 January 2008
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 31 (1), 135-139
- https://doi.org/10.1183/09031936.00105807
Abstract
The pathogenesis of idiopathic pulmonary arterial hypertension (PAH) remains poorly understood. The present authors recently reported that mice with vasoactive intestinal peptide (VIP) gene disruption show a spontaneous phenotype of PAH, with pulmonary vascular remodelling and lung inflammation. To explore the underlying molecular mechanisms in this model, it was examined whether absence of the VIP gene might alter the expression of additional genes involved in the pathogenesis of PAH, as single-gene deletions, in the absence of hypoxia, rarely result in significant pulmonary vascular remodelling. Lung tissue from mice with targeted disruption of the vasoactive intestinal peptide gene (VIP-/- mice) and from control mice was subjected to whole-genome gene microarray analysis, and the results validated with quantitative, real-time PCR. Lungs from VIP-/- mice showed a wide range of significant gene expression alterations, including overexpression of genes that promote pulmonary vascular smooth muscle cell proliferation, underexpression of antiproliferative genes and upregulation of pro-inflammatory genes. In conclusion, vasoactive intestinal peptide is a pivotal modulator of genes controlling the pulmonary vasculature, its deficiency alone resulting in gene expression alterations that can readily explain both the vascular remodelling and associated inflammatory response in pulmonary arterial hypertension. The present findings shed more light on the molecular mechanisms of pulmonary arterial hypertension, and could lead to better understanding of the pathogenesis of human pulmonary arterial hypertension, and hence to improved therapy.Keywords
This publication has 24 references indexed in Scilit:
- The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targetedProceedings of the National Academy of Sciences, 2007
- NFATc3 Mediates Chronic Hypoxia-induced Pulmonary Arterial Remodeling with α-Actin Up-regulationJournal of Biological Chemistry, 2007
- Rho Kinase–Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in RatsCirculation Research, 2007
- Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide GeneCirculation, 2007
- Mediators and modulators of pulmonary arterial hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Vascular endothelial growth factor in the lungAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Autoimmunity and pulmonary hypertension: a perspectiveEuropean Respiratory Journal, 2005
- Inflammation in pulmonary arterial hypertensionEuropean Respiratory Journal, 2003
- Calcineurin-GATA-6 pathway is involved in smooth muscle–specific transcriptionThe Journal of cell biology, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001